Latest Period
Q4 2025
Security Snapshot
Vaxcyte, Inc. - COMMON STOCK (PCVX) Institutional Ownership
CUSIP: 92243G108
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
292
Shares (Excl. Options)
147,544,352
Price
$46.14
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / COMMON STOCK
- Symbol
- PCVX on Nasdaq
- Shares outstanding
- 144,307,555
- Price per share
- $61.75
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 147,544,352
- Total reported value
- $6,807,567,166
- % of total 13F portfolios
- 0.01%
- Share change
- +4,973,518
- Value change
- +$262,484,457
- Number of holders
- 292
- Price from insider filings
- $61.75
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- PCVX - Vaxcyte, Inc. - COMMON STOCK is tracked under CUSIP 92243G108.
- 292 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 292 to 122 between Q4 2025 and Q1 2026.
- Reported value moved from $6,807,567,166 to $1,346,481,855.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 292 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 92243G108?
CUSIP 92243G108 identifies PCVX - Vaxcyte, Inc. - COMMON STOCK in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 92243G108:
Significant Owners of Vaxcyte, Inc. - COMMON STOCK (PCVX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 11% | +13% | $1,015,853,037 | +$204,901,073 | 16,451,061 | +25% | FMR LLC | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 10% | -12% | $472,013,392 | -$57,168,819 | 13,104,203 | -11% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $426,531,754 | 12,964,491 | RA Capital Management, L.P. | 31 Mar 2025 | |||
| T. Rowe Price Investment Management, Inc. | 8.6% | +37% | $520,196,135 | +$137,268,465 | 11,296,333 | +36% | T. Rowe Price Investment Management, Inc. | 31 Dec 2025 |
| BlackRock, Inc. | 7.6% | $323,263,490 | 9,825,638 | BlackRock, Inc. | 31 Mar 2025 | |||
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $421,416,800 | 7,252,053 | Vanguard Capital Management | 31 Mar 2026 |
As of 31 Dec 2025, 292 institutional investors reported holding 147,544,352 shares of Vaxcyte, Inc. - COMMON STOCK (PCVX). This represents 102% of the company’s total 144,307,555 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Vaxcyte, Inc. - COMMON STOCK (PCVX) together control 82% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 9.6% | 13,834,514 | +11% | 0.03% | $638,324,485 |
| JANUS HENDERSON GROUP PLC | 9.3% | 13,387,188 | +2.2% | 0.28% | $617,730,753 |
| VANGUARD GROUP INC | 8.4% | 12,193,986 | -1% | 0.01% | $562,630,515 |
| T. Rowe Price Investment Management, Inc. | 7.8% | 11,296,333 | +36% | 0.33% | $521,213,000 |
| RA CAPITAL MANAGEMENT, L.P. | 7.4% | 10,724,599 | -10% | 5.1% | $494,832,998 |
| BlackRock, Inc. | 7.1% | 10,246,378 | +2.9% | 0.01% | $472,767,877 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.1% | 5,966,310 | +19% | 0.05% | $275,285,543 |
| STATE STREET CORP | 3.5% | 4,980,005 | +4.1% | 0.01% | $229,777,431 |
| Paradigm Biocapital Advisors LP | 2.8% | 4,068,020 | +7.5% | 5% | $187,698,443 |
| Deep Track Capital, LP | 2.8% | 4,000,000 | +33% | 4.2% | $184,560,000 |
| D. E. Shaw & Co., Inc. | 2.5% | 3,631,053 | -15% | 0.13% | $167,536,785 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 2.5% | 3,539,717 | -5.2% | 0.68% | $163,322,542 |
| Kynam Capital Management, LP | 2% | 2,922,335 | -4.9% | 8.8% | $134,836,537 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,866,305 | -0.61% | 0.01% | $132,271,037 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.2% | 1,725,000 | +418% | 0.12% | $79,591,500 |
| Caligan Partners LP | 1.2% | 1,704,815 | 7.2% | $78,660,164 | |
| Polar Capital Holdings Plc | 1.2% | 1,672,783 | +303% | 0.35% | $77,182,208 |
| Pivotal bioVenture Partners Investment Advisor LLC | 0.95% | 1,372,425 | 0% | 24% | $63,323,690 |
| MAVERICK CAPITAL LTD | 0.94% | 1,354,237 | +5% | 0.67% | $62,484,495 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.9% | 1,293,830 | +0.03% | 0.01% | $59,697,316 |
| NORGES BANK | 0.85% | 1,228,939 | 0.01% | $56,703,245 | |
| Eversept Partners, LP | 0.83% | 1,197,722 | -16% | 3.1% | $55,262,893 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.81% | 1,175,339 | -30% | 0.01% | $54,232,000 |
| UBS Group AG | 0.76% | 1,093,593 | +29% | 0.01% | $50,458,382 |
| JPMORGAN CHASE & CO | 0.75% | 1,085,519 | -31% | 0% | $50,085,850 |
Institutional Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 23,177,344 | $1,346,481,855 | +$134,321,130 | $58.11 | 122 |
| 2025 Q4 | 147,544,352 | $6,807,567,166 | +$262,484,457 | $46.14 | 292 |
| 2025 Q3 | 141,285,706 | $5,088,913,432 | -$216,599,261 | $36.02 | 282 |
| 2025 Q2 | 147,479,114 | $4,794,596,759 | -$48,097,035 | $32.51 | 292 |
| 2025 Q1 | 133,025,604 | $5,021,104,716 | -$42,905,782 | $37.76 | 302 |
| 2024 Q4 | 140,784,610 | $11,525,526,197 | +$183,138,339 | $81.86 | 318 |
| 2024 Q3 | 136,507,040 | $15,592,116,896 | +$1,498,526,683 | $114.27 | 325 |
| 2024 Q2 | 122,578,572 | $9,264,040,265 | +$268,135,107 | $75.51 | 264 |
| 2024 Q1 | 119,065,967 | $8,130,427,051 | +$1,115,777,265 | $68.31 | 249 |
| 2023 Q4 | 103,087,407 | $6,473,142,685 | +$69,029,370 | $62.80 | 223 |
| 2023 Q3 | 101,381,209 | $5,166,522,410 | +$77,032,504 | $50.98 | 202 |
| 2023 Q2 | 99,996,517 | $4,993,540,992 | +$865,860,362 | $49.94 | 194 |
| 2023 Q1 | 84,121,058 | $3,152,798,116 | +$159,886,756 | $37.48 | 186 |
| 2022 Q4 | 81,609,487 | $3,913,093,743 | +$1,140,362,544 | $47.95 | 197 |
| 2022 Q3 | 56,496,728 | $1,356,264,990 | +$122,059,625 | $24.00 | 121 |
| 2022 Q2 | 51,432,581 | $1,119,137,255 | +$31,274,087 | $21.76 | 103 |
| 2022 Q1 | 49,852,918 | $1,203,855,921 | +$69,029,421 | $24.15 | 86 |
| 2021 Q4 | 44,718,114 | $1,063,493,543 | +$32,023,661 | $23.79 | 84 |
| 2021 Q3 | 43,198,231 | $1,095,966,337 | -$195,558 | $25.37 | 77 |
| 2021 Q2 | 43,222,434 | $972,744,067 | -$14,050,462 | $22.51 | 74 |
| 2021 Q1 | 44,022,105 | $869,193,186 | +$26,485,491 | $19.75 | 73 |
| 2020 Q4 | 42,260,768 | $1,118,933,017 | +$58,331,379 | $26.57 | 83 |
| 2020 Q3 | 37,761,937 | $1,857,382,730 | +$103,777,823 | $49.38 | 60 |
| 2020 Q2 | 35,950,832 | $1,126,753,000 | +$1,126,753,000 | $31.61 | 38 |